Información de la revista
Original article
Open Access
Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin
El inhibidor de la xantina oxidorreductasa, topiroxostat, mejora la lesión de los podocitos al inhibir la reducción de nefrina y podoplanina
Ying Zhanga, Yoshiyasu Fukusumia, Mutsumi Kayabaa, Takashi Nakamurab, Ryusuke Sakamotob, Naoki Ashizawac, Hiroshi Kawachia,
a Department of Cell Biology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
b Pharmacological Study Group, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan
c Biological Research Group, Research Department, Medical R&D Division, Fuji Yakuhin, Saitama, Japan

Artículo

This article is available in English

Xanthine oxidoreductase inhibitor topiroxostat ameliorates podocyte injury by inhibiting the reduction of nephrin and podoplanin

Ying Zhang, Yoshiyasu Fukusumi, Mutsumi Kayaba, Takashi Nakamura, Ryusuke Sakamoto, Naoki Ashizawa, Hiroshi Kawachi
10.1016/j.nefro.2020.10.011
Nefrologia. 2021;41:539-47
Idiomas
Nefrología